Radiopharma business to invest CAD 94.5 million to double RUBY-FILL production capacity

Jubilant's Radiopharma business will invest CAD 94.5 million to modernize and expand its Kirkland, Québec facility and double production capacity of its flagship product RUBY-FILL®.

Thu 8 Oct 2026

Investment Amount

CAD 94.5 million

Government Support

CAD 23.8 million

RUBY-FILL® Customer Base

doubled in the last 3 years

What was announced

Jubilant Draximage Inc., a subsidiary of the company's wholly owned subsidiary Jubilant Pharma Limited, announced an investment of CAD 94.5 million to modernize and expand its Kirkland, Québec facility and increase production capacity across its radiopharmaceutical portfolio pipeline. Specifically, the investment is aimed at doubling the production capacity of its flagship product RUBY-FILL®. The Government of Canada will provide financial support of CAD 23.8 million to this project through the Strategic Response Fund's innovation funding stream. All amounts in the release are in Canadian dollars.

The numbers

• Investment announced: CAD 94.5 million
• Government of Canada financial support: CAD 23.8 million
• Production capacity of RUBY-FILL®: aimed to be doubled
• RUBY-FILL® customer base: has doubled in the last 3 years
• Radiopharmacies in the US network: 45
• People across the globe: around 5,500

What RUBY-FILL® and the portfolio do

RUBY-FILL® enables the on-site production of Rubidium-82 for cardiac PET imaging, which helps clinicians assess coronary artery disease. The Technetium-99m (99mTc) diagnostic portfolio supports a broad range of SPECT imaging procedures. The company says these products play a role in disease detection, diagnosis, staging and treatment planning across oncology, cardiology and neurology. In the therapeutic space, its Iodine-131 products have long supported treatment of thyroid disease, thyroid cancer and neuroblastoma through targeted delivery of radiation to diseased tissue.

Why the company is expanding

The release states the business continues to see very strong demand for RUBY-FILL® and that the customer base has doubled in the last 3 years. It says this expansion will allow Jubilant to fulfil the elevated demand. Harsher Singh, CEO, Jubilant Radiopharma business, said the investment recognises the business's innovation capabilities in Nuclear Medicine and the role the sector plays in advancing diagnostic and therapeutic treatments, and that the project will build capability in Quebec, create and secure high-value jobs, and ensure a reliable supply of essential radiopharmaceutical products in Canada and around the world.

The facility

The Kirkland facility is described as the only site in Canada producing these product categories. The investment will support modernization and expansion of the facility, including the installation of state-of-the-art production equipment, enabling Jubilant Radiopharma to double its manufacturing capacity to meet growing global demand for RUBY-FILL®.

About the Radiopharma business

Jubilant Radiopharma comprises development, manufacturing and commercialisation of products through its Radiopharmaceuticals business, and distribution through a national network of Radiopharmacies. The release describes its Radiopharmacies business as the second largest radiopharmacy network in the US, with 45 pharmacies distributing nuclear medicine products to national Group Purchasing Organisations, regional health systems, stand-alone imaging centres, cardiologists and hospitals.

Points to keep in mind

• The announcement is a stated plan; the release notes that such statements about plans and objectives are forward-looking, based on estimates and anticipated effects of future events, and that actual results may differ materially.
• The investment amount and the government support are both in Canadian dollars, so they are not rupee amounts.
• The release does not put a timeline on the expansion, and does not quantify the revenue or earnings expected from the added capacity.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.